BioSpace News Archive

BioAge Labs, Inc. (“BioAge”), a clinical-stage biotechnology company developing therapeutic candidates for metabolic diseases, such as obesity, by targeting the biology of aging, today announced preclinical data for its lead product candidate azelaprag, an orally available small molecule agonist of the apelin receptor APJ, in combination with incretin agonists for the treatment of obesity.

Senseonics Holdings, Inc., a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring systems for people with diabetes, announced business updates and provided its full year 2024 financial outlook.

Jaguar Health, Inc. announced the voting results of the Company’s Annual Meeting of Stockholders held June 21, 2024.

PTC Therapeutics, Inc. announced that on June 17, 2024, the company approved non-statutory stock options to purchase an aggregate of 1,380 shares of its common stock and 6,260 restricted stock units, each representing the right to receive one share of its common stock upon vesting, to nine new employees.

argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP).

The ALS Therapy Development Institute (ALS TDI), a nonprofit biotech dedicated to ending amyotrophic lateral sclerosis (ALS), has used mapping technology from Esri, the global leader in location intelligence, to develop the ALS Trial Navigator.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme”) today announced that argenx received U.S. Food and Drug Administration (FDA) approval for VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) co-formulated with ENHANZE®, Halozyme’s proprietary recombinant human hyaluronidase enzyme, rHuPH20, for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP).

Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, has today released a key research whitepaper entitled Antibody-drug conjugates - Global Clinical Trial Landscape.

Medtronic plc, a global leader in healthcare technology, is presenting a comprehensive body of new data at the American Diabetes Association’s 84th Scientific Sessions that showcases the benefits of the MiniMed™ 780G system.

Data from a retrospective observational study conducted using the electronic health record at the Cleveland Clinic, shows that real-world weight loss can be associated with a reduced risk of obesity-related cancers.